Compare Stocks: XBIT, IRON, IVVD, and FHTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$4.14 -1.4%	$5.45	$3.27 ▼ $7.61	$245.85M	2.86	355,942 shs	502,030 shs
IRON Disc Medicine	$69.53 +0.5%	$76.82	$40.00 ▼ $99.50	$2.67B	0.97	492,754 shs	1.06 million shs
IVVD Invivyd	$0.76 +1.2%	$0.76	$0.53 ▼ $3.07	$222.63M	0.81	3.73 million shs	6.27 million shs
XBIT XBiotech	$2.19 +0.5%	$2.26	$2.09 ▼ $3.44	$66.77M	0.85	50,154 shs	66,070 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	0.00%	-6.33%	-40.94%	-0.24%	-13.75%
IRON Disc Medicine	0.00%	-0.76%	-11.81%	-1.78%	+13.93%
IVVD Invivyd	0.00%	-3.84%	-20.56%	-22.13%	-34.32%
XBIT XBiotech	0.00%	0.00%	-5.19%	-5.19%	-17.98%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FHTX Foghorn Therapeutics	$4.14 -1.4%	$5.45	$3.27 ▼ $7.61	$245.85M	2.86	355,942 shs	502,030 shs
IRON Disc Medicine	$69.53 +0.5%	$76.82	$40.00 ▼ $99.50	$2.67B	0.97	492,754 shs	1.06 million shs
IVVD Invivyd	$0.76 +1.2%	$0.76	$0.53 ▼ $3.07	$222.63M	0.81	3.73 million shs	6.27 million shs
XBIT XBiotech	$2.19 +0.5%	$2.26	$2.09 ▼ $3.44	$66.77M	0.85	50,154 shs	66,070 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FHTX Foghorn Therapeutics	0.00%	-6.33%	-40.94%	-0.24%	-13.75%
IRON Disc Medicine	0.00%	-0.76%	-11.81%	-1.78%	+13.93%
IVVD Invivyd	0.00%	-3.84%	-20.56%	-22.13%	-34.32%
XBIT XBiotech	0.00%	0.00%	-5.19%	-5.19%	-17.98%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FHTX Foghorn Therapeutics	2.75	Moderate Buy	$11.67	181.80% Upside
IRON Disc Medicine	2.77	Moderate Buy	$110.18	58.47% Upside
IVVD Invivyd	2.33	Hold	$8.00	959.18% Upside
XBIT XBiotech	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XBIT, IRON, IVVD, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/16/2026	IRON Disc Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$79.00 ➝ $86.00
9/14/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/10/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
9/10/2026	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/10/2026	IRON Disc Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$128.00
9/10/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00
9/8/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/2/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$88.00 ➝ $100.00
9/1/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FHTX Foghorn Therapeutics	$30.91M	7.95	N/A	N/A	($1.92) per share	-2.16
IRON Disc Medicine	N/A	N/A	N/A	N/A	$19.52 per share	N/A
IVVD Invivyd	$53.43M	4.17	N/A	N/A	$1.04 per share	0.73
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FHTX Foghorn Therapeutics	-$74.28M	-$0.98	N/A	N/A	N/A	-175.78%	N/A	-31.17%	11/4/2026 (Estimated)
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	11/5/2026 (Estimated)
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
XBIT XBiotech	-$45.54M	-$1.48	N/A	N/A	N/A	N/A	-31.62%	-30.29%	N/A

Latest XBIT, IRON, IVVD, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/13/2026	Q2 2026	XBIT XBiotech	$0.03	-$0.22	-$0.25	-$0.22	$7.00 million	N/A
8/6/2026	Q2 2026	FHTX Foghorn Therapeutics	-$0.2450	-$0.10	+$0.1450	-$0.10	$6.81 million	$16.10 million
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FHTX Foghorn Therapeutics	N/A	3.36	3.36
IRON Disc Medicine	0.09	24.14	24.14
IVVD Invivyd	N/A	5.87	5.87
XBIT XBiotech	N/A	33.15	33.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FHTX Foghorn Therapeutics	61.55%
IRON Disc Medicine	83.70%
IVVD Invivyd	70.36%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
FHTX Foghorn Therapeutics	9.02%
IRON Disc Medicine	3.76%
IVVD Invivyd	12.25%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FHTX Foghorn Therapeutics	106	59.38 million	54.03 million	Optionable
IRON Disc Medicine	165	38.39 million	36.95 million	Not Optionable
IVVD Invivyd	122	294.76 million	258.65 million	Optionable
XBIT XBiotech	87	30.49 million	21.10 million	Optionable

XBIT, IRON, IVVD, and FHTX Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average - What's Next?

September 15, 2026 | americanbankingnews.com

XBiotech (NASDAQ:XBIT) Shares Cross Below 200-Day Moving Average - Time to Sell?

September 3, 2026 | marketbeat.com

XBiotech (NASDAQ:XBIT) Share Price Passes Above 50 Day Moving Average - Here's What Happened

August 26, 2026 | marketbeat.com

XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

June 15, 2026 | globenewswire.com

XBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ Radar

May 14, 2026 | tipranks.com

XBiotech: Q4 Earnings Snapshot

March 13, 2026 | chron.com

XBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?

October 28, 2025 | msn.com

XBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders

August 28, 2025 | finance.yahoo.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XBIT, IRON, IVVD, and FHTX Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

$4.14 -0.06 (-1.43%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.14 +0.00 (+0.12%)

As of 09/18/2026 07:30 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Disc Medicine NASDAQ:IRON

$69.53 +0.35 (+0.51%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$69.40 -0.13 (-0.18%)

As of 09/18/2026 07:38 PM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Invivyd NASDAQ:IVVD

$0.76 +0.01 (+1.22%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.76 +0.01 (+0.75%)

As of 09/18/2026 07:58 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

XBiotech NASDAQ:XBIT

$2.19 +0.01 (+0.46%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.18 -0.01 (-0.46%)

As of 09/18/2026 07:30 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIT, IRON, IVVD, and FHTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIT, IRON, IVVD, and FHTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIT, IRON, IVVD, and FHTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XBIT, IRON, IVVD, and FHTX Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

Disc Medicine NASDAQ:IRON

Invivyd NASDAQ:IVVD

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIT, IRON, IVVD, and FHTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIT, IRON, IVVD, and FHTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIT, IRON, IVVD, and FHTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XBIT, IRON, IVVD, and FHTX Company Descriptions

Foghorn Therapeutics NASDAQ:FHTX

Disc Medicine NASDAQ:IRON

Invivyd NASDAQ:IVVD

XBiotech NASDAQ:XBIT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools